TACR3
Neuromedin-K receptor
As of the edition of 20 October 2026, TACR3 (neuromedin-K receptor, UniProt P29371) has 4 drugs tested at it and 6 companies on the list, 3 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P29371
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Cancer; Hormones; Inherited and neonatal; Urinary and reproductive; Mental health; Pregnancy and women's health; Nervous system; Digestive system
- Registered trials of its drugs
- 60
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fezolinetant | Marketed | Phase 3 | Ends 2034 |
| Elinzanetant | Marketed | Phase 3 | Ends 2030 |
| Pavinetant | Stopped | Phase 2 | none listed |
| Talnetant | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 2 |
| Engaged | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Astellas | Route B |
| AstraZeneca | Route A |
| Bayer | Route B |
The other 3 companies at TACR3
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at TACR3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.